Statiny v onkologii

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Statins in incology
Authors

SVOBODA Marek VYSKOČIL Jiří NOVÁKOVÁ Jana

Year of publication 2005
Type Article in Periodical
Magazine / Source Klinická farmakologie a farmacie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords statins;HMG-CoA;human tumours;oncogenesis
Description Statins are the most frequently used hypolipidaemic drugs, lowering cholesterol by inhibition of the key enzyme of cholesterol biosynthesis, the 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA). This enzyme is responsible for the production of mevalonic acid, the main precursor of cholesterol synthesis. A number of clinical trials show that statins are well tolerated, relatively safe and very efficient drugs that significantly decrease cardiovascular morbidity and mortality in patients suffering from hypercholesterolaemia, which is the main indication for prescription of statins. Within the last five years, the results of preclinical research have proven the pleiotropic effects of statins in cell systems which are due to their direct or indirect influence on regulation of mechanisms such as the cell cycle, differentiation and apoptosis. These physiological processes play an important role in oncogenesis and, therefore, the role of statins in oncology is being seriously discussed.

You are running an old browser version. We recommend updating your browser to its latest version.

More info